Clinical Trials Browser

OTHER × ibrutinib × Myeloid × Clear all

Anemia, Aplastic, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT03267186 2023-08-01

Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02415608 2018-09-20

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Phase 2 Terminated

4 enrolled 14 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

Clinical Trials

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis